OOIR: Observatory of International Research

Papers

(The H4-Index of Trends in Cancer is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Turning Cold into Hot: Firing up the Tumor Microenvironment	543
Circular RNAs in Cancer: Biogenesis, Function, and Clinical Significance	382
Senescent Cells in Cancer Therapy: Friends or Foes?	242
Glioblastoma Stem Cells: Driving Resilience through Chaos	210
3D In Vitro Model (R)evolution: Unveiling Tumor–Stroma Interactions	208
Exosomes as a Multicomponent Biomarker Platform in Cancer	172
Clinical Development of BRAF plus MEK Inhibitor Combinations	164
Cancer Epigenetics, Tumor Immunity, and Immunotherapy	163
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View	156
Necroptosis and tumor progression	155
Targeting Glycosylation: A New Road for Cancer Drug Discovery	145
Targeting EMT in Cancer with Repurposed Metabolic Inhibitors	139
Gut Microbiota in Cancer Immune Response and Immunotherapy	131
RNA Splicing and Cancer	130
MGMT Status as a Clinical Biomarker in Glioblastoma	127
Promoter DNA Hypermethylation and Paradoxical Gene Activation	127
Emerging Mechanisms by which EMT Programs Control Stemness	121
Advanced Prostate Cancer: Treatment Advances and Future Directions	118
Tumour Cell Secretome in Chemoresistance and Tumour Recurrence	96
Molecular Tumor Boards in Clinical Practice	91
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy	89
Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle	88
Extracellular Vesicles in Cancer Detection: Hopes and Hypes	85
Better together: circulating tumor cell clustering in metastatic cancer	84
Tumor Plasticity and Resistance to Immunotherapy	83

Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy	82
Precision therapy for RET-altered cancers with RET inhibitors	82
Enhancing the Efficacy of Glutamine Metabolism Inhibitors in Cancer Therapy	81
Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?	80
Targeting ferroptosis in pancreatic cancer: a double-edged sword	75
Fat and Furious: Lipid Metabolism in Antitumoral Therapy Response and Resistance	74
Tunneling Nanotubes: The Fuel of Tumor Progression?	72
Mitochondrial Stress Response and Cancer	69
Revisiting the HIF switch in the tumor and its immune microenvironment	66
Tweak to Treat: Reprograming Bacteria for Cancer Treatment	66
TRAIL of Hope Meeting Resistance in Cancer	66
Zebrafish Xenografts for Drug Discovery and Personalized Medicine	65
Ferroptosis and Photodynamic Therapy Synergism: Enhancing Anticancer Treatment	63
Targeting CAFs to overcome anticancer therapeutic resistance	63
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm	59
Targeting SUMO Signaling to Wrestle Cancer	58
FTO in cancer: functions, molecular mechanisms, and therapeutic implications	56
Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases	55
Cirrhosis: A Questioned Risk Factor for Hepatocellular Carcinoma	54
Pharmacological Targeting of IRE1 in Cancer	54
Metabolic Reprogramming in Anticancer Drug Resistance: A Focus on Amino Acids	53
Inflammation: the incubator of the tumor microenvironment	53
Autophagy Regulates Stress Responses, Metabolism, and Anticancer Immunity	53
Challenges in glioblastoma research: focus on the tumor microenvironment	51
Targeting the Mevalonate Pathway in Cancer	49
Utilizing chemokines in cancer immunotherapy	49
C1q+ macrophages: passengers or drivers of cancer progression	49